We’ve put together a clear, at-a-glance comparison of Apoquel and Cytopoint for relieving atopic itch in dogs, covering their mechanisms of action, duration of effect, and side-effect profiles.

| Item | Apoquel | Cytopoint |
|---|---|---|
| Administration form | Oral tablet | Subcutaneous injection |
| Mechanism of action | JAK enzyme inhibition (semi-broad) | Neutralization by IL-31 antibody (narrow target) |
| Onset of effect | Relatively rapid onset of effect | Within 48 hours (1–2 days) |
| Duration of effect | Maintained by taking once daily | 4–8 weeks |
| Administration cycle | Twice a day for the first 2 weeks, then once a day | Monthly hospital visit |
| Minimum age of use | Veterinary judgment based on individual condition | No restriction (all ages possible) |
| Key precautions | Regular blood & urine tests needed to monitor for infection & benign tumors | Side effect reports are very rare |
Actual application is determined by veterinary examination and the individual's condition.

Three Things to Check Before Starting Treatment
Before starting Apoquel or Cytopoint, be sure to check these three things: - Infections: If there are hidden skin infections or ear infections, they should be treated first and then re-evaluated. - Tumor history: Apoquel broadly modulates immune signals, and there are reports of increased benign skin tumors. If your pet has a history of tumors, Cytopoint, which has a narrower range of action and fewer side effects, may be more suitable. - Parasitic infections: Parasitic itching, such as that caused by Demodex or mange, will not be resolved by these treatments. Self-diagnosing and administering medication without a veterinarian's examination can prolong symptoms.


A veterinarian who majored in veterinary medicine at Khon Kaen University, Thailand, and completed the IVSA program at North Carolina State University in the United States. Drawing on clinical experience at animal hospitals, he works in the pet healthcare field and is dedicated to building a digital care environment that connects pet parents with veterinarians.
Share
[1] Gonzales AJ et al., Oclacitinib (APOQUEL®) is a novel Janus kinase inhibitor with activity against cytokines involved in allergy, Journal of Veterinary Pharmacology and Therapeutics, 2014
[2] Michels GM et al., A blinded, randomized, placebo-controlled, dose determination trial of lokivetmab in client owned dogs with atopic dermatitis, Veterinary Dermatology, 2016
[3] Miller, Griffin, Campbell, Muller and Kirk's Small Animal Dermatology, 7th Ed, Chapter 8 Hypersensitivity Disorders